Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Enrolling by invitation × Doxorubicin × Clear all

Phase

Status

Completed 185 Unknown 50 Active not recruiting 38 Recruiting 31 Terminated 24 Not yet recruiting 4 Withdrawn 2 Suspended 2 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

zilucoplan 1 zanidatamab 1 tislelizumab 1 sitravatinib 1 rozanolixizumab 1 pamiparib 1 lenvatinib 1 fludarabine phosphate 1 fludarabine 1 exemestane 1 epigallocatechin gallate 1 durvalumab 1 aumolertinib 1 atropine sulfate-diphenoxylate hydrochloride drug combination 1 Vincristine 1 Temozolomide 1 Tamoxifen 1 Sodium Chloride 1 R-CHOP protocol 1 Prednisone 1 Pemetrexed 1 Omeprazole 1 Melphalan 1 Loperamide 1 Letrozole 1 High-Energy Shock Waves 1 HMPL-013 1 Gastroscopy 1 Etoposide 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07258680 2025-12-02

BrEto-TCL

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Enrolling by invitation

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡